Novel Technologies News

Novel Technologies News Archive

Life-like “on-a-chip” model of human perfused blood vessels offers new solutions for toxicity testing, drug discovery, and precision medicine Life-like “on-a-chip” model of human perfused blood vessels offers new solutions for toxicity testing, drug discovery, and precision medicine

Neuchâtel, Switzerland, 01 October 2019 – A unique, three-dimensional model of human blood vessels has been demonstrated to accurately assess a key stage in the development of inflammation and vascular disorders such as atherosclerosis. The microvessel-on-a-chip, jointly developed and optimized by Philip Morris International (PMI) and organ-on-a-chip specialists MIMETAS (Leiden, The Netherlands), can be used under flow to measure the attachment of immune cells to the blood vessel wall—an important feature of early onset atherogenesis—as well as gain unique mechanistic insights through analysis of transcriptomic profiles. In addition, the model has been shown to be effective in applications such as the toxicological assessment of consumer products.